Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase (Q44686239)

5 December 2017

Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase (English)

1 reference

5 December 2017

3

1 reference

5 December 2017

2

Patrick Vallance

1 reference

5 December 2017

Rainer H Böger

1

1 reference

5 December 2017

1 December 2003

1 reference

Atherosclerosis. Supplements

5 December 2017

1 reference

5 December 2017

4

1 reference

5 December 2017

1-3

1 reference

5 December 2017

4

1 reference

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Endogenous nitric oxide synthase inhibitors are responsible for the L -arginine paradox

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Regression or progression. Dependency on vascular nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

Dietary l -Arginine Reduces the Progression of Atherosclerosis in Cholesterol-Fed Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900027-8

7 January 2021

10.1016/S1567-5688(03)00027-8

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

14664896